Cerecor Inc. (CERC) Financial Analysis & Valuation | Quarter Chart
Cerecor Inc. (CERC)
CERCPrice: $2.93
Fair Value: 🔒
🔒score
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-8... more
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatment... more
Description
Shares
| Market Cap | $38.63M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Michael Cola |
| IPO Date | 2015-11-13 | CAGR | — |
| Employees | 30 | Website | www.cerecor.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.1% | Total Yield | -0.1% |
CERC chart loading...
Fundamentals
Technicals
| Enterprise Value | $-10.56M | P/E Ratio | -3.38 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.3 |
| P/CF Ratio | -1.52 | P/FCF Ratio | -1.85 |
| EPS | $-0.87 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.18% | ROA | -0.16% |
| ROCE | -0.29% | Current Ratio | 12.44 |
| Quick Ratio | 12.44 | Cash Ratio | 4.57 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | — |